Lisata Therapeutics Completes Enrollment In Its Phase 2a BOLSTER Trial Of Certepetide In First-Line Cholangiocarcinoma
Portfolio Pulse from Benzinga Newsdesk
Lisata Therapeutics has completed enrollment in its Phase 2a BOLSTER trial for certepetide in first-line cholangiocarcinoma nearly six months ahead of schedule. Top-line data is expected by mid-2025, and a second-line cholangiocarcinoma arm has been added to the trial.
July 16, 2024 | 12:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lisata Therapeutics has completed enrollment in its Phase 2a BOLSTER trial for certepetide in first-line cholangiocarcinoma nearly six months ahead of schedule. This milestone could accelerate the timeline for potential approval and commercialization, positively impacting the stock price.
The early completion of enrollment in the Phase 2a BOLSTER trial indicates strong interest and potential efficacy of certepetide, which could lead to faster approval and commercialization. This is likely to positively impact Lisata's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100